Anzeige
Mehr »
Freitag, 16.05.2025 - Börsentäglich über 12.000 News
Empire bei 89 Mio. USD - Doch dieser Titan-Explorer mit Drilltreffern notiert noch unter 6 Mio.?€!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40KHL | ISIN: US64113L2025 | Ticker-Symbol:
NASDAQ
15.05.25 | 19:37
2,020 US-Dollar
0,00 % 0,000
1-Jahres-Chart
NETCAPITAL INC Chart 1 Jahr
5-Tage-Chart
NETCAPITAL INC 5-Tage-Chart

Aktueller Chart NETCAPITAL Aktie

Chart vergleichen mit:

Firmenname, WKN, ISIN oder Aktien-Kürzel

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%
Chart-Typ:
Zeitraum:
 
NETCAPITAL INC-Investoren interessieren sich auch für diese Wertpapiere
Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Announces Registration of Acne Products in the United Kingdom and Launch of the Products in Leading U.K. Pharmacy ChainBOULDER, CO / ACCESS Newswire / April 22, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous...
► Artikel lesen
Pre-market Movers: 2seventy bio, Sonoma Pharmaceuticals, Tenon Medical, Arvinas, NET Power Inc.LONDON (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 09.00 A.M. ET).In the Green 2seventy bio, Inc. (TSVT) is up over 76% at $4.93. Sonoma...
► Artikel lesen
Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Secures Extensive U.K. Regulatory Clearances of Key Wound Care and Dermatology Products by the Medicines & Healthcare Products Regulatory AgencyBOULDER, CO / ACCESS Newswire / March 10, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous...
► Artikel lesen
Jaguar Health, Inc.: Jaguar Health Reports First Quarter 2025 FinancialsThe combined net Q1 2025 revenue of approximately $2.2 million for prescription and non-prescription products, including license revenue, decreased approximately 6% versus net Q1 2024 revenue of $2.4...
► Artikel lesen
Jaguar Health, Inc.: Jaguar Health to Hold Investor Webcast Thursday, May 15 at 4:15 PM Eastern Regarding Q1 2025 Financials & Corporate UpdatesClick here to registerCompany plans to file its Earnings Report on May 15, 2025 on Form 10-Q for the quarter ended March 31, 2025 SAN FRANCISCO, CA / ACCESS Newswire / May 14, 2025 / Jaguar Health,...
► Artikel lesen
Jaguar Health, Inc.: Jaguar Health Celebrates National Pet Cancer Awareness Month: With its Supportive Cancer Care Drugs, Jaguar is Dedicated to the Health and Wellbeing of People and DogsCompany's Canalevia®-CA1 (crofelemer delayed-release tablets) prescription drug is FDA conditionally approved for treatment of chemotherapy-induced diarrhea (CID) in dogs and is the first and only treatment...
► Artikel lesen
Windtree Therapeutics Regains Compliance with Nasdaq Listing RulesWARRINGTON, Pa., March 24, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating biotech...
► Artikel lesen
Windtree Therapeutics: Windtree Announces Istaroxime Notice of Allowance from the U.S. Patent and Trademark Office for Acute Heart FailureWARRINGTON, Pa., March 04, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative...
► Artikel lesen
Windtree Therapeutics, Inc. Announces Reverse Stock SplitWARRINGTON, Pa., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT) ("Windtree" or the "Company"), a biotechnology company focused on advancing early and late-stage innovative...
► Artikel lesen